BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
INFUSION O
REACTIONS O
and O
CARDIOPULMONARY O
ARREST O
WARNING O
: O
SERIOUS O
INFUSION O
REACTIONS O
and O
CARDIOPULMONARY O
ARREST O
Infusion B-NonOSE_AE
Reactions I-NonOSE_AE
: O
Serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
with O
the O
administration O
of O
Erbitux O
in O
approximately O
3 O
% O
of O
patients O
in O
clinical O
trials O
, O
with O
fatal B-NonOSE_AE
outcome O
reported O
in O
less O
than O
1 O
in O
1000 O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
. O
] O

Immediately O
interrupt O
and O
permanently O
discontinue O
Erbitux O
infusion O
for O
serious O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

[ O
See O
Dosage O
and O
Administration O
( O
2.4 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
. O
] O

Cardiopulmonary B-NonOSE_AE
Arrest I-NonOSE_AE
: O
Cardiopulmonary B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
and/or O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
occurred O
in O
2 O
% O
of O
patients O
with O
squamous B-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
head I-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
treated O
with O
Erbitux O
and O
radiation O
therapy O
in O
Study O
1 O
and O
in O
3 O
% O
of O
patients O
with O
squamous B-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
head I-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
treated O
with O
European O
Union O
( O
EU O
) O
-approved O
cetuximab O
in O
combination O
with O
platinum-based O
therapy O
with O
5-fluorouracil O
( O
5-FU O
) O
in O
Study O
2 O
. O

Closely O
monitor O
serum O
electrolytes O
, O
including O
serum O
magnesium O
, O
potassium O
, O
and O
calcium O
, O
during O
and O
after O
Erbitux O
administration O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.2 O
, O
5.6 O
) O
, O
Clinical O
Studies O
( O
14.1 O
) O
. O
] O

EXCERPT O
: O
WARNING O
: O
SERIOUS O
INFUSION O
REACTIONSand O
CARDIOPULMONARY O
ARREST O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Serious O
infusion O
reactions O
, O
some O
fatal O
, O
occurred O
in O
approximately O
3 O
% O
of O
patients O
. O

( O
5.1 O
) O
* O
Cardiopulmonary O
arrest O
and/or O
sudden O
death O
occurred O
in O
2 O
% O
of O
patients O
with O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
treated O
with O
Erbitux O
and O
radiation O
therapy O
and O
in O
3 O
% O
of O
patients O
with O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
treated O
with O
cetuximab O
in O
combination O
with O
platinum-based O
therapy O
with O
5-fluorouracil O
( O
5-FU O
) O
. O

Closely O
monitor O
serum O
electrolytes O
, O
including O
serum O
magnesium O
, O
potassium O
, O
and O
calcium O
, O
during O
and O
after O
Erbitux O
administration O
. O

( O
5.2 O
, O
5.6 O
) O

